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Looking back on an exciting scientific enterprise can be 
a very nostalgic experience for any scientist, and this 
is particularly true for us in the case of cloning the leptin 
receptor. We had been very interested in tapping into 
the molecular mechanisms that regulate body weight. 
The molecular biology of body weight regulation was still 
largely a black box in the early 1990s when compared to 
other fields in which we had worked, such as immunol- 
ogy. This was largely due to the fact that body weight 
regulation is a "whole organism" phenomenon that is 
difficult o break down into convenient in vitro systems. 
Therefore, the identification of "factors" and their corre- 
sponding genes was quite challenging. Fortunately, rev- 
olutions in genomics technologies were looming and, 
therefore, we were optimistic about gaining a molecular 
foothold in this area. It was clear to many of us at the 
time that cloning the genes that corresponded to the 
mouse ob and db loci would provide such a key entry 
point. Mice mutant for the ob and db loci (which have 
a dramatic obesity syndrome) had been studied for de- 
cades. Obtaining a molecular understanding of the se- 
vere consequences on whole body weight regulation 
seen in these mutant mice would be a pivotal advance 
in the field. The first breakthrough came from the work 
of Jeff Friedman and colleagues when they used a posi- 
tional cloning approach to clone the ob locus and define 
its gene product, leptin. This made it very likely that the 
receptor for leptin would correspond to the genetically 
defined db locus. 
There was immediate and very justified excitement 
about the identification of the leptin protein. However, 
it soon became clear from ongoing work in a number 
of laboratories (including our work at Millennium) that 
most obese humans are not deficient in leptin and actu- 
ally produce it at higher levels. This implied that a better 
understanding of mammalian body weight regulation 
and, hence, human obesity, would come from the clon- 
ing of the leptin receptor and an understanding of signal- 
ing events downstream of this receptor. Needless to 
say, we were not the only ones to recognize the implica- 
tions of this. In fact, nearly every pharmaceutical com- 
pany, large biotechnology company, and many aca- 
demic labs began a pursuit of the leptin receptor. 
Given the intense interest and clarity of the goal, we 
then found ourselves in a race. It may not be politically 
correct to refer to an exciting scientific endeavor as a 
race, but in this case we think it is justifiable. However, 
this in no way should detract from the sensibility of such 
an intense scientific effort, because it is the entire group 
of scientists participating in this endeavor that directly 
or indirectly moves the field forward by assuring even- 
tual success. 
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Immediately after the cloning of leptin was published, 
we began mapping out an initial strategy to clone the 
leptin receptor. It was clear we were not in a position 
to further refine the position of the db locus on the 
mouse genome in time, and, therefore, we could not 
use a positional cloning strategy with the tools in hand. 
Using a biochemical approach, with leptin binding as a 
tool, seemed the appropriate strategy. We had experi- 
ence with several expression cloning techniques from 
our days at either Genentech in David Goeddel's lab 
(Lou) or Harvard in Philip Leder's lab (Bob). We tinkered 
with several specific approaches with which we were 
familiar, including a relatively novel approach (at the 
time) successfully used by John Flanagan. This ap- 
proach involved tagging the leptin protein with alkaline 
phosphatase (AP), which could then be easily tracked 
in binding studies. John and his post-doc (Hwai-Jong 
Cheng) talked us through this approach in more detail, 
and it became clear that this approach had potential 
advantages in the case of the leptin receptor (which 
would later become one of the earliest examples of 
successful expression cloning of a receptor from an 
actual tissue source, as opposed to a cell line). We 
therefore took the gamble of putting the majority of our 
efforts and resources into this approach. 
The longest period of time was spent identifying, via 
binding studies, an appropriate tissue source from 
which to make the expression cloning libraries. This key 
data came from both an extensive search of tissues and 
cell lines using our AP-tagged leptin proteins and also 
1251-1eptin binding data from our collaborators at 
Roche. The AP-leptin tissue binding data from our team 
came through the efforts of Suzy Dembski and Jim 
Deeds, and the 1251-1eptin binding data came through 
the efforts organized by Rene Devos. Through these 
studies we identified the choroid plexus (a thin layer 
of tissue within the ventricles of the brain involved in 
transport across the blood brain barrier) as a tissue 
that had significant leptin binding. The presence of this 
binding activity in db/db mice caused us considerable 
concern. The reason for this became apparent later 
when we found that the mutation in this mouse strain 
only affects signaling of the receptor and not leptin bind- 
ing. Given the small tissue mass of the choroid plexus, 
it was necessary to sacrifice 600 rodents, which required 
6 people from our team to dissect these cells from within 
the rodent brain ventricles over the course of a week 
(our binding studies in larger animals, which involved 
several trips to the slaughter house, were unconvincing). 
The library itself was made from the isolated choroid 
plexus RNA by Janice Culpepper and Frederick Clark. 
Craig Muir and Sean Sanker supplied the automation 
technology to create large numbers of pooled cDNA. 
With the team having prepared both the expression li- 
brary and also large stocks of AP-tagged leptin, we then 
began the expression cloning. After about six weeks we 
began to get enticing positives from one of the library 
fractions. Further pool subdivision and careful binding 
studies with specific individual clones made it clear that 
we had cloned the leptin receptor. Sequence analysis 
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showed it to be a class I cytokine receptor. The first 
receptor we cloned had a very short intracellular domain. 
This was confusing at first, since it was unlikely to be 
capable of signal transduction. However, over the next 
week or so, we identified otherwise identical forms of 
the receptor except with a large intracellular domain. 
We surmised from this that some forms of the receptor 
are used for signaling in the hypothalamus, while others 
are used for transport across the blood brain barrier. 
Genome mapping studies using this cloned gene as a 
probe (done by Karen Moore) also indicated that this 
clone was likely the db locus. 
We wrote the manuscript in one weekend and it ap- 
peared in print three weeks after we submitted it to Cell, 
in recognition of the well-known intensity of this race. 
Interestingly, the only referee comments of significant 
concern stemmed from rumors the referees had heard 
about competing groups also cloning the receptor; spe- 
cifically, that these "other" receptors looked nothing like 
ours. Fortunately, a quick conversation with Ben Lewin 
made it clear that Cell did not expect us to address such 
rumors. This was fortunate, because these rumors later 
turned out to be incorrect. We then established defini- 
tively the relationship between our receptor and the db 
locus and described the nature of the mutation in the 
original db/db mouse. This work was published in a 
follow-up paper in Cell six weeks after the publication 
of the cloning and genomic mapping of the receptor. 
During the period between the construction of the ex- 
pression library and sending off the completed manu- 
script to Ceil (about two months), Lou worked approxi- 
mately 18 hr a day and learned a lot about the biology 
of sleep deprivation as well. Nevertheless, it was one 
of the most exciting periods of our scientific careers, 
and a memory that our entire team holds very dear. 
It has also been very exciting to see the explosion of 
obesity research and the progress that has been made 
since the initial leptin/leptin receptor papers. The fuse 
for this explosion has not only been these papers, but 
also a number of others, including the characterization 
of other mouse monogenic obesity syndromes and the 
identification of human counterparts. The new genomics 
technologies that are now available, such as whole ge- 
nome transcriptional profiling of pathways and mutation 
detection in humans, have also accelerated work dra- 
matically compared to what would have been possible 
a decade ago. As a result, not only has our scientific 
understanding of the molecular mechanisms regulating 
body weight improved, but even in the lay population 
there is a greater acceptance of obesity as a chronic 
disease in which genetics plays an important role, as 
opposed to simply a weakness of will. Also, the impact 
of these many discoveries on anti-obesity efforts within 
the pharmaceutical industry cannot be overstated. Most 
pharmaceutical companies have increased their efforts 
in metabolic disease, since it now appears possible that 
manipulation of specific protein molecules may reduce 
body weight. We are confident hat in the science and 
treatment of obesity, the best is yet to come. 
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Summary 
The ob gene product, leptin, is an important circulating 
signal for the regulation of body weight. To identify 
high affinity leptin-binding sites, we generated a series 
of leptin-alkaline phosphatase (AP) fusion proteins as 
well as r~l]leptin. After a binding survey of cell lines 
and tissues, we identified leptin-binding sites in the 
mouse choroid plexus. A cDNA expression library was 
prepared from mouse choroid plexus and screened 
with a leptin-AP fusion protein to identify a leptin re- 
ceptor (OB-R). OB-R is a single membrane-spanning 
receptor most related to the gp 130 signal-transducing 
component of the IL-6 receptor, the G-CSF receptor, 
and the LIF receptor. OB-R mRNA is expressed not 
only in choroid plexus, but also in several other tis- 
sues, including hypothalamus. Genetic mapping of the 
gene encoding OB-R shows that it is within the 5.1 cM 
interval of mouse chromosome 4 that contains the db 
locus. 
Introduction 
The recently cloned mouse obesity (ob) gene appears to 
encode an adipose tissue-derived signaling factor for 
body weight homeostasis (Zhang et al., 1994). Mice that 
are homozygous for mutations in this gene exhibit a pro- 
found obesity resulting from defects in energy expendi- 
ture, food intake, and nutrient partitioning (reviewed by 
Bray and York, 1979). Several recent studies have shown 
that recombinant OB protein (leptin) purified from Esche- 
richia coil can correct the obesity related phenotypes in 
oblob mice when exogenously administered (Campfield 
et al., 1995; Pelleymounter et al., 1995; Halaas et al., 1995; 
Stephens et al., 1995). Weight-reducing effects of recom- 
binant leptin were also observed in normal mice and mice 
with diet-induced obesity. Although the target issues that 
mediate the effects of leptin have not yet been defined, 
the work of Campfield et al. (1995) and Stephens et al. 
(1995) demonstrate that leptin introduced into the lateral 
or third brain ventricle is effective at low doses, arguing 
for a direct central affect of the leptin molecule. 
Another well-characterized recessive obesity mutation, 
diabetes (db), also results in profound and early onset 
obesity (reviewed by Bray and York, 1979). Mice homozy- 
gous for the db mutation exhibit an obesity phenotype 
nearly identical to the phenotype of oblob mice (Coleman, 
1978). Parabiosis studies with oblob and dbldb mice indi- 
cate that dbldb mice may be defective in reception of the 
ob gene product signal (Coleman, 1973). These data have 
led to speculation that the db gene may encode the recep- 
tor for leptin, although the available data would also be 
consistent with db encoding a component of the leptin 
signal transduction pathway. 
Recent studies have suggested that obese humans and 
rodents (other than ob/ob mice) are not defective in their 
ability to produce leptin mRNA or protein and generally 
produce higher levels than lean individuals (Maffei et al., 
1995; Considine et al., 1995; L0nnqvist et al., 1995; Hamil- 
ton et al., 1995). These data suggest that resistance to 
normal or elevated levels of leptin may be more important 
than inadequate leptin production in human obesity. We 
have therefore begun a characterization of the mechanism 
of leptin signal reception. As a first step toward this goal, 
we have identified and cloned a high affinity receptor for 
the leptin molecule. 
Results 
Localization of Leptin-Binding Sites 
To search for the leptin receptor, we generated both puri- 
fied [~2Sl]leptin a d a series of leptin--alkaline phosphatase 
(AP) fusion proteins. To generate the leptin-AP fusion pro- 
teins, cDNAs encoding the mouse and human leptin pro- 
teins were inserted into the expression vectors APtag-2 
and APtag-3 (see Expedmental Procedures). Insertion into 
the expression vector APtag-2 resulted in fusion proteins 
with leptin at the N-terminus and placental AP at the 
C-terminus (OB-AP). Insertion into the vector APtag-3 re- 
sulted in fusion proteins with AP at the N-terminus fused 
to the predicted mature form of the leptin protein at the 
C-terminus (AP-OB) (Figure 1A). Figure 1B shows that 
both murine AP-OB and OB-AP are secreted proteins 
and that each is produced at the predicted molecular mass 
of approximately 81 kDa. 
After a search of mammalian cell lines and tissues, re- 
producible binding of the AP-OB fusion proteins and 
r2Sl]leptin was observed in the mouse choroid plexus. For 
the [12Sl]leptin studies, coronal brain sections were taken 
and tissue slices incubated with 0.5 nM [~251]leptin. Tissues 
were then washed and exposed to film. Figure 2 shows 
strong [~2Sl]leptin binding to the choroid plexus in both the 
